Impax Laboratories Inc. received a nonapprovable letter from the FDA regarding its New Drug Application and subsequent submissions for carbidopa/levodopa extended-release tablets. The FDA’s decision was primarily based on unresolved issues related to product nomenclature and the potential for drug errors resulting from confusing Impax’s product with other marketed forms of carbidopa/levodopa.

From our partners at VerusMed
verusmed.com

Sponsored by The Doctor’s Channel